November 19 advisory committee meeting will explore the scientific, clinical, and regulatory challenges of diagnostic technologies designed to detect known and potentially unknown pathogens.

On November 19, 2026, the U.S. Food and Drug Administration (FDA) will convene its Microbiology Devices Panel to examine the potential use of pathogen-agnostic sequencing (PAS) in infectious-disease emergency preparedness and response. The public meeting will bring together scientific, clinical, regulatory, and public health perspectives to address the development, validation, and implementation of these emerging diagnostic technologies.

The meeting partially fulfills a requirement established under Section 3302 of the Food and Drug Omnibus Reform Act of 2022 (FDORA).

Preparing for the Next Emerging Pathogen

Conventional infectious-disease diagnostics generally require advance knowledge of the pathogen being investigated. Pathogen-agnostic sequencing offers a different approach by examining genetic material within a specimen without requiring a predetermined microbial target.

This capability could be particularly valuable during the early stages of an outbreak, when healthcare providers recognize an unusual pattern of illness but have not yet identified its cause. However, translating that capability into reliable diagnostic information presents substantial scientific, technical, and regulatory challenges.

What FDA Wants to Learn

FDA’s published questions for the panel address four principal areas. The potential advantages and risks of using PAS during public health emergencies, how laboratories and healthcare providers could incorporate PAS into outbreak response, the essential design and performance characteristics of reliable PAS diagnostic systems, and how analytical software and genomic databases can remain reliable as pathogen sequences change.

The discussion will also consider reporting criteria, representative-organism validation, contamination monitoring, laboratory infrastructure, and communication of findings to public health authorities.

Validating a Technology Designed to Detect the Unknown

One of the most significant challenges involves establishing diagnostic performance when the potential detection targets are not fully defined. Conventional molecular diagnostic assays can be evaluated against specific organisms. Pathogen-agnostic sequencing systems, however, may analyze thousands of potential microbial sequences.

How can manufacturers demonstrate reliable performance across such a broad range of organisms, particularly those that have not yet been characterized?

FDA’s briefing materials examine potential approaches, including representative-organism testing and computational performance assessments, while acknowledging important uncertainties regarding their applicability.

Maintaining a Validated Bioinformatics System

Another important consideration involves the relationship between sequencing technology, analytical software, and genomic reference databases. These databases must evolve as new organisms are identified and scientific understanding of existing pathogens advances. However, modifying an analytical system to improve detection of one organism could inadvertently affect its ability to detect others.

This creates a fundamental regulatory science challenge: maintaining confidence in diagnostic performance while allowing the system to adapt rapidly to emerging biological threats. For manufacturers, this raises important questions concerning software validation, configuration management, change control, risk management, and the evidence needed to support system updates.

Implications for the Medical Device Industry

The panel discussion has potential implications extending beyond sequencing instrument manufacturers. Developers of diagnostic assays, specimen preparation systems, laboratory automation technologies, bioinformatics software, genomic databases, and analytical quality control tools all have a role in the broader pathogen-agnostic sequencing ecosystem.

For regulatory affairs and quality assurance professionals, the meeting offers an opportunity to better understand the scientific challenges that may influence future regulatory approaches to these technologies.

The advisory committee’s recommendations are nonbinding. The meeting is intended to inform FDA’s scientific and regulatory considerations rather than establish new regulatory requirements or evaluate a specific product for market authorization.

Meeting Information

Date: Thursday, November 19, 2026

Time: 9:00 a.m.–4:15 p.m. Eastern Time

Format: Hybrid — in-person and virtual

Location: FDA White Oak Campus, Silver Spring, Maryland

Public Docket: FDA-2026-N-8692

The meeting is open to the public. The public comment submission period closed on November 12, 2026.

FDA has published the meeting agenda, executive summary, panel questions, meeting roster, and public comments.

Official FDA Resources:

Read more about pathogen-agnostic sequencing

A New Approach for Infectious-Disease Detection

Pathogen-Agnostic Sequencing and the Future of Infectious Disease PreparednessDetecting the Unknown. Connecting the Signals. Preparing for the Future. What if we could recognize an emerging infectious disease before we knew what pathogen was causing it? Advances in...

The Wolverine Peptide Stack: What We Know

Promoted for faster healing and injury recovery, two experimental peptides are attracting growing consumer interest despite limited human clinical evidence and unresolved safety questions.The promise sounds almost too good to be true: faster recovery from injuries,...

Hims & Hers Moves Into Selling Unapproved Peptides

Telehealth company's planned expansion illustrates how quickly commercial markets are responding to changes in federal oversight of experimental therapies.Hims & Hers Health plans to begin offering new wellness treatments in November, including an unapproved...

When Political Priorities and FDA Science Collide

HHS proposes expanding access to six unapproved peptides despite objections from FDA scientists. This raises questions about regulatory oversight, patient safety, and the distinction between enforcement discretion and drug approval.The Trump administration is moving...

What to Know about FDA’s Revised Peptide Guidance

What Manufacturers Need to Know Seventeen revised draft product-specific guidance documents reflect FDA's evolving scientific and regulatory approach to generic peptide drug development. On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17...

The Regulatory Dilemma of Experimental Peptides

As demand for experimental peptides grows, a fundamental question confronts federal regulators. Can access to unapproved drug products expand without compromising the standards intended to protect patients? The growing popularity of experimental peptides such as...

FDA Moves Toward New Peptide Compounding Policy

FDA Moves Toward New Peptide Compounding PolicyAgency submits proposed policy change for White House review as HHS signals support for expanded access to experimental peptides Nearly three months after an FDA advisory committee recommended adding six experimental...

Peptides square tile
Pharma square image
Pharma Recalls
Dietary Supplements MDP
Biologics Square Image